MarketPulse

biotech stock

2 articles
The Motley FoolThe Motley Fool··David Jagielski, Cpa

CRISPR Therapeutics Stock Slumps 9% Despite Casgevy Approval and Strong Cash Position

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.
VRTXCRSPgene editingCasgevy
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges on Positive Phase 3 Psilocybin Trial Results

Compass Pathways stock surged 44% after positive Phase 3 trial results for psilocybin depression therapy. FDA application expected by end of 2024.
CMPSFDA approvaltreatment-resistant depression